1999 to 2004
Dr. Jeffrey Molldrem discovers PR1 peptide; conducts early clinical trials on AML, CML, MDS with NCI sponsorship.


July 2003
Company incorporated. Founders are Jeffrey Molldrem, MD; Ron Garren, MD; Gregory Thayer; Craig Rosenfeld, MD.

March 2004
Company raises $2.1M in Series A financing.


April 2004
Company announces technology transfer deal with University of Texas.


December 2004
Company raises $1M in Series B financing.


August 2005
Company raises $23M in Series C financing.
Article 1 :: Article 2


October 2006
Company receives FDA approval of IND application to initiate Phase 3 trial in AML, and Phase 2 trials in CML and MDS.


January 2007
First patients enrolled in Phase 2 company-sponsored clinical trials on CML and MDS.


April 2007
First patient enrolled in Phase 3 company-sponsored clinical trial on AML.